IL10 and cancer: Different studies have previously revealed hyper-activation and expansion of CD8+ T cells, enhanced production of IFN-γ and peripheral increase of various pro-inflammatory and immune-activating mediators following recombinant IL-10 administration in healthy subjects with LPS-induced endotoxemia and in patients with Crohn’s disease and some cancers.